PDCD1 and neoplasm: Increasing reports have demonstrated the crucial functions of m6A regulators in impairing the CD8+ T cell anti-tumor effect and increasing the resistance to anti-PD-1 therapy (Zhang et al., 2020; Guo et al., 2021).